Xiuning Le

Nov 29, 2024 | nature.com | Fei Zhou |Xiuning Le |Suresh S. Ramalingam

AbstractThe discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nervous system penetrance, are the standard-of-care first-line treatment for advanced-stage EGFR-mutant NSCLC.

Sep 10, 2024 | onclive.com | Xiuning Le

Xiuning Le, MD, PhD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses updated findings from the phase 1/2 SOHO-01 trial (NCT05099172).

Aug 20, 2024 | digitalcommons.library.tmc.edu | Sonia Patel |Monique B. Nilsson |Xiuning Le |Tina Cascone

Home > UTHealth > GSBS > Journal Articles > 412 Clinical Cancer Reserach Humans, Vascular Endothelial Growth Factor A, Neovascularization, Pathologic, Angiogenesis Inhibitors, Neoplasms, Signal Transduction, Tumor Microenvironment DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons COinS...

Aug 20, 2024 | digitalcommons.library.tmc.edu | Sonia Patel |Monique B. Nilsson |Xiuning Le |Hai T. Tran

Purpose: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit.

Oct 27, 2023 | onclive.com | Xiuning Le

Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from the interim analysis of the phase 2 RAMOSE trial (NCT03909334) in patients with TKI-naïve metastatic non–small cell lung cancer (mNSCLC) harboring EGFR mutations. RAMOSE enrolled patients with advanced NSCLC and classical EGFR mutations who had not received prior TKIs or VEGF-directed therapy.